Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRF Image-guided Surgery with Low-dose ICG for Soft Tissue Tumors
NCT06610071Phase 1Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of indocyanine green in dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (SCC) (6 arms). Primary endpoint: 2-year local recurrence rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
indocyanine green
03
Conditions
dermatofibrosarcoma protuberans (DFSP)skin squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT06610071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610071.